» Articles » PMID: 31988902

Noninvasive Prenatal Testing - When Is It Advantageous to Apply

Overview
Journal Biomed Hub
Date 2020 Jan 29
PMID 31988902
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Nowadays it is common sense in obstetrics that an increased risk for pregnancy loss due to invasive testing does not exist. Nonetheless, noninvasive prenatal testing (NIPT) is a hot topic, even though this approach does not provide a reduction of unintentionally induced abortions. NIPT has a number of shortcuts which are highlighted in this review, including: (1) in NIPT placental rather than fetal DNA is studied, (2) NIPT fails in 2-6% of cases, and (3) trisomy 21 accounts for only ∼50% of existing chromosomal aberrations. Thus, we agree with the literature that NIPT is a fascinating possibility to gain information on unborn life from minimal amounts of DNA. However, it remains a pure risk estimation test directed towards the detection of specific chromosomal abnormalities from peripheral blood of the pregnant woman. It is important to highlight that families buying this test, and getting a normal result, may be provided with a false sense of security. Thus, careful and comprehensive genetic counselling should be performed before the test is offered, and should include a clear explanation of the advantages and disadvantages, as well as limitations, compared to other methods.

Citing Articles

Advancements of non-invasive prenatal testing: the role of obstetricians.

Eltabbakh N, Mohasin Y, Jeddy R Front Med (Lausanne). 2024; 11:1388481.

PMID: 38938382 PMC: 11208619. DOI: 10.3389/fmed.2024.1388481.


The Diagnostic, Prognostic, and Therapeutic Potential of Cell-Free DNA with a Special Focus on COVID-19 and Other Viral Infections.

Hovhannisyan G, Harutyunyan T, Aroutiounian R, Liehr T Int J Mol Sci. 2023; 24(18).

PMID: 37762464 PMC: 10532175. DOI: 10.3390/ijms241814163.


Amniotic fluid karyotype analysis and prenatal diagnosis strategy of 3117 pregnant women with amniocentesis indication.

Liu Y, Sun X, Lv G, Liu J, Sun C, Mu K J Comp Eff Res. 2023; :e220168.

PMID: 37256256 PMC: 10402904. DOI: 10.57264/cer-2022-0168.


Retinitis Pigmentosa: Current Clinical Management and Emerging Therapies.

Nguyen X, Moekotte L, Plomp A, Bergen A, van Genderen M, Boon C Int J Mol Sci. 2023; 24(8).

PMID: 37108642 PMC: 10139437. DOI: 10.3390/ijms24087481.


Non-Invasive Prenatal Testing in Germany.

Liehr T, Harutyunyan T, Williams H, Weise A Diagnostics (Basel). 2022; 12(11).

PMID: 36428876 PMC: 9689121. DOI: 10.3390/diagnostics12112816.


References
1.
. Fetal sex pridiction by sex chromatin of chorionic villi cells during early pregnancy. Chin Med J (Engl). 1975; 1(2):117-26. View

2.
Grati F, Malvestiti F, Ferreira J, Bajaj K, Gaetani E, Agrati C . Fetoplacental mosaicism: potential implications for false-positive and false-negative noninvasive prenatal screening results. Genet Med. 2014; 16(8):620-4. DOI: 10.1038/gim.2014.3. View

3.
Tabor A, Vestergaard C, Lidegaard O . Fetal loss rate after chorionic villus sampling and amniocentesis: an 11-year national registry study. Ultrasound Obstet Gynecol. 2009; 34(1):19-24. DOI: 10.1002/uog.6377. View

4.
Weise A, Liehr T . Rapid prenatal aneuploidy screening by fluorescence in situ hybridization (FISH). Methods Mol Biol. 2008; 444:39-47. DOI: 10.1007/978-1-59745-066-9_3. View

5.
Valenti C . Antenatal detection of hemoglobinopathies. A preliminary report. Am J Obstet Gynecol. 1973; 115(6):851-3. DOI: 10.1016/0002-9378(73)90532-2. View